10-Q: Illumina Reports Q2 2026 Results, Revenue Up 9%

Illumina Inc. announced its second quarter 2026 financial results, reporting a 9% increase in total revenue to $1.159 billion, driven by strong performance in consumables and instruments, alongside the integration of SomaLogic.

Summary

• Illumina reported a 9% increase in total revenue for the second quarter of 2026, reaching $1.159 billion, compared to $1.059 billion in the prior year period.
• For the six months ended June 28, 2026, revenue grew 7% to $2.251 billion.
• The acquisition of SomaLogic, completed in January 2026, contributed to the increase in service and other revenue.
• Gross margin for the quarter was 66.4%, up from 65.6% in the prior year, though excluding a prior year impairment charge, it saw a decrease.
• Net income for the quarter was $207 million, a decrease from $235 million in the prior year period.
• Earnings per diluted share were $1.35 for the quarter, down from $1.49 in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with solid revenue growth and strategic acquisition integration, but tempered by increased operating expenses and ongoing macroeconomic uncertainties.

Positives

• Total revenue increased by 9% to $1.159 billion in Q2 2026.
• Product revenue saw an 8% increase to $982 million in Q2 2026.
• Consumables revenue grew 5% to $852 million in Q2 2026.
• Instruments revenue increased by 29% to $130 million in Q2 2026, driven by NovaSeq X and MiSeq i100 shipments.
• Service and other revenue increased by 20% to $177 million in Q2 2026, boosted by SomaLogic's contribution.
• Gross margin improved to 66.4% in Q2 2026 from 65.6% in Q2 2025.
• Operating income increased to $245 million in Q2 2026 from $214 million in Q2 2025.
• The company ended the quarter with $1.040 billion in cash and cash equivalents.

Negatives

• Net income decreased to $207 million in Q2 2026 from $235 million in Q2 2025.
• Diluted earnings per share decreased to $1.35 in Q2 2026 from $1.49 in Q2 2025.
• Revenue from the Greater China region decreased by $7 million in Q2 2026 due to inclusion on the unreliable entities list.
• Excluding a prior year impairment charge, gross margin decreased due to higher tariff costs, increased sales mix towards lower-margin instruments, and higher memory chip and freight costs.
• Selling, general and administrative expenses increased by 17% to $273 million in Q2 2026.

Risks

• Macroeconomic factors such as tariffs, inflation, exchange rate fluctuations, and concerns about economic downturn continue to create uncertainty.
• Inclusion on the unreliable entities list by regulatory authorities in China is impacting revenue from that region.
• Reductions in U.S. government funding for the NIH could negatively impact customers and reduce demand.
• Ongoing armed conflicts, including in the Middle East and Iran, are increasing fuel, energy, and shipping costs.
• Higher costs associated with memory chips used in products are negatively impacting gross margin.
• The company faces risks related to legal and regulatory proceedings, including shareholder derivative complaints and securities class actions.
• Uncertainty regarding the impact of tariffs imposed by the U.S. government and trading partners, and related court proceedings.
• Risks associated with contracts or agreements that might be impacted by the divestiture of GRAIL, Inc.

Future Outlook

The company expects macroeconomic factors, including tariffs, inflation, exchange rate fluctuations, and concerns about economic downturn, to continue to impact sales and results of operations in 2026 and beyond. They are also managing costs related to the Middle East conflict and memory chip prices. The company anticipates that current cash, cash equivalents, short-term investments, cash from operations, and available borrowing capacity will be sufficient to fund near-term capital and operating needs for at least the next 12 months.

Management Comments

• We believe our acquisition of SomaLogic will enhance our presence in the proteomics market and advance our multiomics strategy.
• We continued to make progress toward our key strategic goals focused on a return to revenue growth and improved margin performance by the end of 2027.
• We expect these factors (macroeconomic headwinds, geopolitical instability, etc.) to continue to impact our sales and results of operations in 2026, and beyond, the magnitude and duration of which remains uncertain.
• We intend to seek refunds for IEEPA-related tariffs, and have begun that process, but the timing and amount of recoveries remain uncertain.

Industry Context

StockSavvy.ai notes that Illumina's Q2 2026 results reflect ongoing efforts to integrate its recent SomaLogic acquisition and navigate a challenging macroeconomic environment. The reported revenue growth, particularly in consumables and instruments, aligns with broader trends in the genomics and multiomics space, while the impact of geopolitical and economic factors highlights the industry's sensitivity to global conditions.

Comparison to Industry Standards

• Illumina's revenue growth of 7% year-over-year for the first six months of 2026 is a solid performance in the life sciences tools sector, which has seen varied growth rates among competitors.
• The reported operating margin of 20.2% for YTD 2026 is competitive within the industry, though specific comparisons depend on the product mix and R&D investment levels of peers like Thermo Fisher Scientific or Agilent Technologies.
• The integration of SomaLogic positions Illumina to compete more directly in the growing proteomics market, an area where companies like Thermo Fisher Scientific also have significant investments.
• The company's focus on high-throughput sequencing with the NovaSeq X instrument aligns with the industry trend towards larger-scale genomic studies, a key driver for companies like Oxford Nanopore Technologies.

Legal Proceedings

• Shareholder derivative complaints filed in Delaware Court of Chancery alleging breaches of fiduciary duty related to the GRAIL acquisition.
• Federal securities class actions filed alleging materially false and misleading statements and omissions related to the GRAIL acquisition.
• State securities class actions filed alleging materially false and misleading statements and omissions in registration statements and prospectuses related to the GRAIL acquisition.

Stakeholder Impact

• Shareholders: Potential impact from ongoing litigation and the company's share repurchase programs.
• Employees: Impacted by costs associated with ERP upgrade and potential restructuring charges.
• Suppliers: Potential impact from tariffs and supply chain optimization efforts.
• Creditors: The company is in compliance with covenants under its Revolving Credit Agreement.

Next Steps

• Continue to monitor and evaluate the design and operating effectiveness of key controls related to the ERP system upgrade.
• Seek refunds for IEEPA-related tariffs, with timing and amount of recoveries remaining uncertain.
• Continue to take action to mitigate the impact of tariffs through supply-chain optimization, cost measures, and pricing actions.
• Monitor stockholder lawsuits and revisit litigation demands as warranted.
• The upgraded ERP system is expected to become operational in the first half of 2027.

Key Dates

Recommendation

The company shows solid revenue growth and strategic progress with the SomaLogic acquisition. However, increased operating expenses, ongoing litigation, and macroeconomic uncertainties warrant a cautious 'hold' stance until these factors are more resolved.

Keywords

Genomic Analysis, DNA Sequencing, Proteomics, SomaLogic Acquisition, NovaSeq X, Consumables, Instruments, Life Sciences